The trademark application AVIDITY was filed by Avidity Biosciences, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on June 21, 2022, and it was registered by office on September 28, 2022 without any oppositions.
The application was filed in Danish (English was selected as the second language).
Change of name and address of the trademark registration was recorded on March 9, 2022. Appointment and Replacement of representative of the trademark registration was recorded on February 28, 2024.
The Appeal with reference B R1882/2021-5 was Application partially rejected according to Article 71(1) EUTMR with decision issued on April 11, 2022 by the EUIPO. The Refusal with reference B 018289185 was partially rejected according to Article 7(1)(b) EUTMR with decision issued on September 8, 2021 by the EUIPO.
Goods And Services
The mark was filed in class 5 with following description of goods:
Biological, medicinal and pharmaceutical preparations for medical purposes for accessing and treating human muscle tissue
Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases
Biological, medicinal and pharmaceutical preparations, namely, oligonucleotide-based therapeutics for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Diagnostic preparations, namely for sample preparation, modification and manipulation of cells as well as for labelling, separation, isolation, purification, amplification and/or analysis of natural or synthetic biopolymers, namely nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances for gene modification
Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders
Oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders
Oligonucleotide compounds for use in targeted gene silencing
Drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
Reagents for testing human blood and tissue to detect the presence of genetic diseases and disorders and reactions to therapies
Oligonucleotides, antibodies, in-vitro diagnostics and control reagents for medical purposes, being kit components for testing human blood and tissue to detect the presence of genetic diseases and disorders and reactions to therapies
Kits, containing primarily of reagents, oligonucleotides, in-vitro diagnostic preparations, control reagents, electronic or online manuals and/or instruments for biochemical, molecular biological and immunological testing for the presence of diseases and reactions to therapies.
The mark was filed in class 42 with following description of goods:
Conducting clinical trials in the fields of pharmaceuticals and biotechnology for treating muscle tissue for the treatment of genetic diseases and disorders
Conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials of oligonucleotide-based therapeutics for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases
Conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders related to genetic diseases and disorders
Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology, namely, consultancy for the treatment of genetic diseases and disorders
Consultancy relating to pharmaceutical research and development, namely, consultancy for the treatment of genetic diseases and disorders
Development of pharmaceutical preparations and medicines for targeting and treating muscle tissue for the treatment of genetic diseases and disorders
Services for assessing the efficiency of pharmaceuticals in treating genetic diseases and disorders
Testing of pharmaceuticals for the treatment of genetic diseases and disorders
Providing information about the results of clinical trials for pharmaceutical products for treatment of genetic diseases and disorders
Scientific research for medical purposes, namely, for accessing and treating muscle tissue for the treatment of genetic diseases and disorders
Pharmaceutical product evaluation for treatment of genetic diseases and disorders
Medical research laboratory services for accessing and treating muscle tissue for the treatment of genetic diseases and disorders
Providing medical and scientific research information in the field of pharmaceuticals and clinical trials related to genetic diseases and disorders
Research and development in the pharmaceutical and biotechnology fields, namely, research for accessing and treating muscle tissue for the treatment of genetic diseases and disorders
Research and development in the pharmaceutical and biotechnology fields, namely, research and development of oligonucleotide-based therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases
Research and development in the pharmaceutical and biotechnology fields, namely, research and development of oligonucleotide-based therapeutics for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Research and development for the use of oligonucleotides for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Medical and scientific research services for the use of oligonucleotide for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies and heart muscle diseases
Medical and scientific research services for the use of oligonucleotide for the treatment of muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
Development of pharmaceutical preparations and medicines, namely, the development of oligonucleotide-based therapeutics for accessing and treating muscle tissue for the treatment of genetic diseases and disorders
Scientific research and development related to genetic diseases and disorders
Scientific investigations for medical purposes related to genetic diseases and disorders
Research and development of oligonucleotide drug delivery platforms for use in the treatment of genetic diseases and disorders related to genetic diseases and disorders
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of genetic diseases and disorders related to genetic diseases and disorders
Research and development of oligonucleotide compounds for targeted gene silencing related to genetic diseases and disorders.